Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Targeting Vertebral Compression Fractures

Executive Summary

The treatment of vertebral compression fractures has evolved into a $375 per year industry in the US, almost $500 million worldwide. It is controlled primarily by one company, Kyphon Inc., but there are many other companies offering less expensive vertobroplasty alternatives.

You may also be interested in...



Vertebral Compression Fracture Market Heats Up with New Technologies

Vertebral compression fracture repair is one of the fastest growing segments of the spinal market. New developments in VCF repair promise continued growth, but a shakeup of competitive dynamics is probably also in the future.

Vertebral Compression Fracture Market Heats Up with New Technologies

Vertebral compression fracture repair is one of the fastest growing segments of the spinal market. New developments in VCF repair promise continued growth, but a shakeup of competitive dynamics is probably also in the future.

Kyphon Steps Up

A year ago at this time, a sale to another company was the last thing on the minds of senior executives at St. Francis Medical, one of the leading companies in dynamic stabilization. But interest by large spine companies put a halt to the company's plans to go public and led to an auction that was eventually won by Kyphon. Kyphon's acquisition of St. Francis Medical was one of the device industry's biggest deals in 2006--and just what everyone was waiting for.

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel